Vaccinex, Inc.
VCNX · OTC
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 309.6% | -77.6% | 123.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 74% |
| R&D Expenses | $2 | $3 | $4 | $3 |
| G&A Expenses | $1 | $1 | $2 | $2 |
| SG&A Expenses | $1 | $1 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $4 | $5 | $6 | $5 |
| Operating Income | -$3 | -$5 | -$6 | -$5 |
| % Margin | -1,590.1% | -8,753.8% | -2,466.4% | -4,878.8% |
| Other Income/Exp. Net | $0 | -$1 | $0 | $1 |
| Pre-Tax Income | -$3 | -$6 | -$6 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$6 | -$6 | -$4 |
| % Margin | -1,584% | -11,023.1% | -2,427.2% | -3,747.1% |
| EPS | -1.61 | -2.83 | -3.1 | -2.94 |
| % Growth | 43.1% | 8.7% | -5.4% | – |
| EPS Diluted | -1.61 | -2.83 | -3.1 | -2.94 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 1 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$6 | -$6 | -$4 |
| % Margin | -1,575.1% | -10,976.9% | -2,416.4% | -3,694.2% |